UIH(SH:688271) Sou Hu Cai Jing·2026-02-25 11:06Financial Performance - The company reported a total revenue of 13.821 billion yuan for the year 2025, representing a year-on-year growth of 34.18% [1] - The net profit attributable to the parent company reached 1.888 billion yuan, an increase of 49.60% compared to the previous year [1] - The net profit after deducting non-recurring gains and losses was 1.788 billion yuan, showing a significant growth of 77.01% year-on-year [1] - Basic earnings per share were 2.29 yuan, up by 48.70% from the previous year [1] - The weighted average return on equity was 9.09%, an increase of 2.56 percentage points compared to the same period last year [1] - Key financial indicators such as operating profit, total profit, and net profit attributable to the parent company all saw growth rates exceeding 30% [1] Market Dynamics - The growth in performance was driven by multiple factors, including the normalization and specialization of large-scale medical equipment renewal policies in China, leading to sustained demand for high-end medical imaging and radiation therapy equipment [1] - The company's market share in the domestic market has further increased, maintaining its industry leadership [1] - Internationally, the company experienced rapid growth in key regions such as Europe, North America, Asia-Pacific, and emerging markets, with an increasing brand influence and penetration among high-end clients [1] Product Development - During the reporting period, the company launched significant products including China's first photon-counting spectral CT uCT Ultima and the world's first "imaging" MRI uMR Ultra, along with a new series of ultrasound products [2] - The company has established a comprehensive high-end medical imaging and radiation therapy product lineup covering CT, MR, XR, MI, RT, and ultrasound [2] - Future growth is expected as innovative products are introduced to global markets, key projects are delivered, and the global localization service system matures [2]